Key Takeaways
- Sales headcount is only one component of commercialization cost.
- Right-sizing depends on the market—rare disease and specialty models often look different from broad primary-care launches.
- Hiring too early creates burn; hiring too late creates execution risk.
- Build a capability and sequencing model before locking a budget narrative for the board.
Boards and CEOs frequently ask a version of the same question: what will it cost to commercialize?
The answer begins with a different question: what commercial system does this therapy actually require?
Copying another company’s organizational chart—or estimating cost from sales headcount alone—often produces the wrong investment thesis. See commercial organization strategy.
Cost Beyond the Field Force
A realistic commercialization budget should consider leadership, Medical Affairs, Market Access, patient services, commercial operations, analytics, training, compliance, distribution, systems and launch governance—not only representatives and managers.
Each of those capabilities may be internal, outsourced or phased. The cost structure changes with that design.
Start With Market Requirements
Cost follows the market:
- size and concentration of the treating universe
- diagnostic complexity
- institutional versus community care
- access and specialty pharmacy burden
- patient-support intensity
- competitive dynamics at launch
A concentrated rare disease opportunity may require a focused model. A broader specialty opportunity may require more infrastructure. Neither should be assumed from convention.
Sequencing Determines Spend
Hiring too early creates unnecessary cost. Hiring too late creates execution risk. A commercial organization roadmap should map investment against clinical and regulatory milestones, functional dependencies and launch requirements.
Use the 36-month launch roadmap and commercial leadership timing guidance as planning tools—not universal rules.
What Boards Should Expect
Boards should expect a clear connection between market reality, organizational design and investment—not a single number presented without assumptions. Independent review through commercial due diligence or board advisory can pressure-test those assumptions.
About Joseph McCoy
Joseph McCoy is Founder and Principal Consultant of PharmaKonsult and an executive commercial strategy advisor with more than three decades of pharmaceutical and biotechnology commercial leadership experience across neuroscience, rare disease, endocrinology, institutional healthcare and specialty pharmaceuticals.
